FI904445A0 - Antivirala foereningar. - Google Patents

Antivirala foereningar.

Info

Publication number
FI904445A0
FI904445A0 FI904445A FI904445A FI904445A0 FI 904445 A0 FI904445 A0 FI 904445A0 FI 904445 A FI904445 A FI 904445A FI 904445 A FI904445 A FI 904445A FI 904445 A0 FI904445 A0 FI 904445A0
Authority
FI
Finland
Prior art keywords
foereningar
antiviral
preparation
treatment
methods
Prior art date
Application number
FI904445A
Other languages
English (en)
Inventor
Sylvia Margaret Tisdale
Tuttle Joel Van
Martin John Slater
Susan Mary Daluge
Wayne Howard Miller
Thomas Anthony Krenitsky
George Walter Koszalka
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of FI904445A0 publication Critical patent/FI904445A0/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Local Oxidation Of Silicon (AREA)
  • Element Separation (AREA)
FI904445A 1989-09-11 1990-09-10 Antivirala foereningar. FI904445A0 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898920534A GB8920534D0 (en) 1989-09-11 1989-09-11 Antiviral compounds

Publications (1)

Publication Number Publication Date
FI904445A0 true FI904445A0 (fi) 1990-09-10

Family

ID=10662891

Family Applications (1)

Application Number Title Priority Date Filing Date
FI904445A FI904445A0 (fi) 1989-09-11 1990-09-10 Antivirala foereningar.

Country Status (19)

Country Link
EP (2) EP0671410A1 (fi)
JP (1) JPH03145497A (fi)
KR (1) KR910006293A (fi)
AT (1) ATE135365T1 (fi)
AU (1) AU644095B2 (fi)
CA (1) CA2025009A1 (fi)
DD (1) DD297650A5 (fi)
DE (1) DE69025834D1 (fi)
FI (1) FI904445A0 (fi)
GB (1) GB8920534D0 (fi)
HU (1) HUT54704A (fi)
IE (1) IE903269A1 (fi)
MY (1) MY130035A (fi)
NZ (1) NZ235244A (fi)
PL (1) PL164967B1 (fi)
PT (1) PT95261A (fi)
RU (2) RU2043361C1 (fi)
TW (2) TW246641B (fi)
ZA (1) ZA907187B (fi)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95384C (fi) * 1989-04-06 1996-01-25 Squibb Bristol Myers Co Menetelmä 3'-deoksi-3'-substituoitujen metyylinukleosidien valmistamiseksi ja menetelmässä käytettäviä välituotteita
US5859221A (en) * 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5914396A (en) * 1990-01-11 1999-06-22 Isis Pharmaceuticals, Inc. 2'-O-modified nucleosides and phosphoramidites
US6399754B1 (en) 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US6005087A (en) * 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5872232A (en) * 1990-01-11 1999-02-16 Isis Pharmaceuticals Inc. 2'-O-modified oligonucleotides
US5670633A (en) * 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
WO1991015498A2 (en) * 1990-04-04 1991-10-17 Nycomed Imaging As Nucleoside derivatives
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5792844A (en) * 1990-07-27 1998-08-11 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent nitrogen atoms
US5677437A (en) * 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5618704A (en) * 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
AU1254892A (en) * 1990-12-18 1992-07-22 Sloan-Kettering Institute For Cancer Research Novel synthesis of 2'-"up" fluorinated 2''-deoxy-arabinofuranosylpurines
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5965722A (en) * 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US6307040B1 (en) 1992-03-05 2001-10-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5393841A (en) * 1993-11-09 1995-02-28 Shell Oil Company Dissimilar arm asymmetric radial or star block copolymers for adhesives and sealants
US6413410B1 (en) 1996-06-19 2002-07-02 Lifescan, Inc. Electrochemical cell
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
PT917879E (pt) * 1997-11-22 2002-12-31 Roche Diagnostics Gmbh Processo melhorado para estabilizacao de proteinas
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
ATE344271T1 (de) * 1998-02-25 2006-11-15 Univ Emory 2'-fluoronukleoside
BR0114837A (pt) 2000-10-18 2006-05-09 Pharmasset Ltd nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
US7132453B2 (en) * 2002-03-15 2006-11-07 Vanderbilt University Method of using prostacyclin to treat respiratory syncytial virus infections
AU2003290598A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US7928210B2 (en) 2007-03-01 2011-04-19 Siemens Medical Solutions Usa, Inc. Nucleoside based proliferation imaging markers
EP2669290A1 (en) 2009-03-02 2013-12-04 Alnylam Pharmaceuticals Inc. Nucleic Acid Chemical Modifications
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
EP2937420A1 (en) * 2014-04-23 2015-10-28 Synbias Pharma AG Method for the synthesis of clofarabine
JP6983814B2 (ja) * 2016-12-14 2021-12-17 ヤマサ醤油株式会社 抗ウイルス活性を示すヌクレオシド誘導体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
CA1340645C (en) * 1987-04-17 1999-07-13 Victor E. Marquez Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus

Also Published As

Publication number Publication date
RU2043361C1 (ru) 1995-09-10
MY130035A (en) 2007-05-31
HUT54704A (en) 1991-03-28
IE903269A1 (en) 1991-03-27
AU6235090A (en) 1991-03-14
PL164967B1 (pl) 1994-10-31
GB8920534D0 (en) 1989-10-25
JPH03145497A (ja) 1991-06-20
CA2025009A1 (en) 1991-03-12
DD297650A5 (de) 1992-01-16
DE69025834D1 (de) 1996-04-18
TW246641B (fi) 1995-05-01
PT95261A (pt) 1991-05-22
TW226333B (fi) 1994-07-11
NZ235244A (en) 1992-11-25
AU644095B2 (en) 1993-12-02
ZA907187B (en) 1992-05-27
ATE135365T1 (de) 1996-03-15
RU94002475A (ru) 1996-11-10
EP0417999A1 (en) 1991-03-20
EP0671410A1 (en) 1995-09-13
EP0417999B1 (en) 1996-03-13
KR910006293A (ko) 1991-04-29
PL286820A1 (en) 1991-04-22

Similar Documents

Publication Publication Date Title
FI904445A0 (fi) Antivirala foereningar.
MY104575A (en) Therapeutic nucleosides.
MY104043A (en) Therapeutic nucleosides.
IL78553A (en) Therapeutic compositions of phosphonylmethoxyalkyl adenines
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
MY107843A (en) Anti-viral compounds.
UA29429C2 (uk) Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини
PT777669E (pt) Utilizacao de succinato de 4-(2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-ciclopenteno-1-metanol como agente antiviral
DK0406745T3 (da) Antibiotiske GE 2270 faktorer A1, A2, A3 og H
PT87004A (pt) Process for the preparation of compositions for the treatment of viral infections and composites 3'-azide-2',3'-didesoxy-in osine and 3'-fluoro-2',3'-didesoxyguanosine
PT81387A (en) Process for preparing pharmaceutical compositions containing 1--beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide useful for treating human viral disfases
ATE183508T1 (de) Therapeutische nukleoside
MX9303985A (es) Nucleosidos terapeuticos.
DE3462891D1 (en) New pyrimidine derivatives endowed with antiviral activity
HUT52110A (en) Process for producing compounds with antiviral effect and pharmaceutical compositions comprising same
FI943295A (fi) Piliostigma thonningii -uutteet, niiden käyttö ja niitä sisältävät formuloinnit
ES2078380T3 (es) Oligofosfatos de accion antiviral.
TH10822EX (th) นิวคลีโอไซด์ซึ่งใช้ในการรักษาโรค
TH9840A (th) สารประกอบต้านไวรัส

Legal Events

Date Code Title Description
FA Application withdrawn

Owner name: THE WELLCOME FOUNDATION LIMITED